Saghmos Therapeutics reposted this
Please join me and Stephen Grant MD, Former Deputy Director, FDA, Division of Cardiology and Nephrology and currently our Chief Regulatory Officer, at the Morgan Stanley 22nd Annual Global Healthcare Conference, on Wednesday, September 4th at 2:35 pm Eastern Time to learn more about our Phase 3-ready cardiovascular-kidney metabolic asset, ST-62516, for reducing the risk of cardiorenal complications after PCI. We will host 1-on-1 meetings September 4-6th at the conference; you can reach us via Morgan Stanley conference platform or LinkedIn message. The presentation will be webcast live at: https://lnkd.in/e6mxQ8jm, with a replay available shortly thereafter. https://lnkd.in/ezHaEMWJ #phase3 #cardiorenal #CKM #acutekidneyinjury